

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2021 BMJ Publishing Group Ltd and European Alliance of Associations for Rheumatology. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorial

- 823** Tenascin-C, a novel target to inhibit new bone formation in axial spondyloarthritis, linked with inflammation, mechanical strain and tissue damage
M Van Mechelen, R Lories

Thinking the unthinkable

- 825** Rheumatology in 2049: the age of *all data*
J Mucke, P Sewerin, M Schneider

Review

- 828** Tissue physiology revolving around the clock: circadian rhythms as exemplified by the intervertebral disc
H Morris, C F Gonçalves, M Dudek, J Hoyland, Q-J Meng

Recommendation

- 840** EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)
F Costantino, L Carmona, M Boers, M Backhaus, P V Balint, G A Bruyn, R Christensen, P G Conaghan, R J O Ferreira, J L Garrido-Castro, F Guillemín, H B Hammer, D van der Heijde, A Iagnocco, M C Kortekaas, R BM Landewé, P Mandl, E Naredo, W A Schmidt, L Terslev, C B Terwee, R Thiele, M-A D'Agostino

Rheumatoid arthritis

- 848** Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka, D van der Heijde, J A Simon, H S B Baraf, U Kumar, F Matzkies, B Bartok, L Ye, Y Guo, C Tasset, J S Sundry, A Jahreis, M C Genovese, N Mozaffarian, R B M Landewé, S-C Bae, E C Keystone, P Nash

- 859** Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study
H TW Smeele, E Röder, H M Wintjes, L JC Kranenburg-van Koppen, J MW Hazes, RJEM Dolhain

- 865** JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
P G Traves, B Murray, F Campigotto, R Galien, A Meng, J A Di Paolo

876



EDITOR'S CHOICE

- Genetic variants shape rheumatoid arthritis-specific transcriptomic features in CD4⁺ T cells through differential DNA methylation, explaining a substantial proportion of heritability
E Ha, S-Y Bang, J Lim, J H Yun, J-M Kim, J-B Bae, H-S Lee, B-J Kim, K Kim, S-C Bae

Inflammatory arthritis

- 884** Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis
I Gessl, M Popescu, V Schimpl, G Supp, T Deimel, M Durechova, M Hucke, M Loiskandl, P Studenic, M Zauner, J S Smolen, D Aletaha, P Mandl

Spondyloarthritis

- 891** Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes enthesal new bone formation through activation of Hippo signalling in ankylosing spondylitis
Z Li, S Chen, H Cui, X Li, D Chen, W Hao, J Wang, Z Li, Z Zheng, Z Zhang, H Liu

Pain

- 903** Maintaining musculoskeletal health using a behavioural therapy approach: a population-based randomised controlled trial (the MAmMOTH Study)
G J Macfarlane, M Beasley, N Scott, H Chong, P McNamee, J McBeth, N Basu, P C Hannaford, G T Jones, P Keeley, G J Prescott, K Lovell

Systemic sclerosis

- 912** Autoantibodies targeting telomere-associated proteins in systemic sclerosis
B L Adler, F Boin, P J Wolters, C O Bingham, A A Shah, C Greider, L Casciola-Rosen, A Rosen

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

Member since 2008
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 920** Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma



OPEN ACCESS

R L Ross, C Corinaldesi, G Migneco, I M Carr, A Antanaviciute, C W Wasson, A Carriero, J H W Distler, S Holmes, Y M El-Sherbiny, C S McKimmie, F Del Galdo

Epidemiology

- 930** Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry



OPEN ACCESS

A Strangfeld, M Schäfer, M A Gianfrancesco, S Lawson-Tovey, J W Liew, L Ljung, E F Mateus, C Richez, M J Santos, G Schmajuk, C A Scirè, E Sirotich, J A Sparks, P Sufka, T Thomas, L Trupin, Z S Wallace, S Al-Adely, J Bachiller-Corral, S Bhana, P Cacoub, L Carmona, R Costello, W Costello, L Gossec, R Grainger, E Hachulla, R Hasseli, J S Hausmann, K L Hyrich, Z Izadi, L Jacobsohn, P Katz, L Kearsley-Fleet, P C Robinson, J Yazdany, P M Machado, COVID-19 Global Rheumatology Alliance

- 943** Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts



OPEN ACCESS

A Y S Wong, B MacKenna, C E Morton, A Schultze, A J Walker, K Bhaskaran, J P Brown, C T Rentsch, E Williamson, H Drysdale, R Croker, S Bacon, W Hulme, C Bates, H J Curtis, A Mehrkear, D Evans, P Inglesby, J Cockburn, H I McDonald, L Tomlinson, R Mathur, K Wing, H Forbes, R M Eggo, J Parry, F Hester, S Harper, S J W Evans, L Smeeth, I J Douglas, B Goldacre, The OpenSAFELY Collaborative

Letters

- 953** SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists

R Priori, G Pellegrino, S Colafrancesco, C Alessandri, F Ceccarelli, M Di Franco, V Riccieri, R Scrivo, A Sili Scavalli, F R Spinelli, F Conti

- 954** Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

D J Wallace, F Figueras, W A Wegener, D M Goldenberg

- 956** Validation of the 2019 ACR/EULAR criteria for IgG4-related disease in a Japanese kidney disease cohort: a multicentre retrospective study by the IgG4-related kidney disease working group of the Japanese Society of Nephrology



OPEN ACCESS

T Saeki, T Nagasawa, Y Ubara, Y Taniguchi, M Yanagita, S Nishi, M Nagata, Y Yamaguchi, T Saito, H Nakashima, M Kawano

- 957** Bone loss in patients with SAPHO syndrome: a preliminary study

X Chen, M Wang, W Cui, Z Wang

Electronic pages

- e103** Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study

J Inamo

- e104** Response to: 'Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Inamo

D Alpizar Rodriguez, T R Lesker, B Gilbert, T Strowig, A Finckh

- e105** Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease

S-W Lai, Y-H Kuo, K-F Liao

- e106** Response to: 'Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease' by Lai *et al*

L Fardet, I Petersen, I Nazareth

- e107** MS score in systemic juvenile idiopathic arthritis: suitable for routine use?

H Chi, Z Wang, C Yang, Y Su

- e108** Response to: 'MS score in systemic juvenile idiopathic arthritis: suitable for routine use?' by Chi *et al*

F Minoia, A Ravelli

- e109** Correspondence to 'Time to change the primary outcome of lupus trials'

S Oon, M Huaq, M Nikpour

- e110** Response to Correspondence to 'Time to change the primary outcome of lupus trials' by Oon *et al*

F A Houssiau

- e111** Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?
G Coiffier, A Martel, J-D Albert, A Lescoat, A Bleuzen, A Perdriger, M De Bandt, F Maillot
- e112** Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier *et al*
S Jousse-Joulin, M A D'Agostino, A Hočevar, E Naredo, L Terslev, S Ohrndorf, A Iagnocco, W A Schmidt, S Finzel, Z Alavi, G A W Bruyn, on behalf the Salivary Gland subgroup of the OMERACT US working group
- e113** Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis
C Campochiaro, G De Luca, M De Santis
- e114** Response to: 'Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis' by Campochiaro *et al*
L Spielmann, F Séverac, A Meyer
- e115** Correspondence on 'Standardisation of myositis-specific antibodies: where are we today?'
M Infantino, M Manfredi, N Bizzaro
- e116** Response to: 'Comment on: standardisation of myositis-specific antibodies: where are we today?' by Infantino *et al*
J Rönnelid, F Espinosa-Ortega, I E Lundberg
- e117** Novel NLRP12 variant presenting with familial cold autoimmunity syndrome phenotype
L Gupta, S Ahmed, B Singh, S Prakash, S Phadke, A Aggarwal
- e118** Response to: 'Novel NLRP12 variant presenting with familial cold autoimmunity syndrome phenotype' by Gupta *et al*
C Eijkelboom, N M Ter Haar, J Frenkel, M Gattorno
- e119** How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials
I Parodis, M Nikpour
- e120** Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
E Raschi, I C Antonazzo, E Poluzzi, F De Ponti
- e121** Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab
F Muratore, C Salvarani